Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Valneva ( (VALN) ) has provided an update.
On March 26, 2026, Valneva SE announced it will have a significant presence at the 26th World Vaccine Congress in Washington, D.C., taking place from March 31 to April 2, 2026. Led by CEO Thomas Lingelbach, senior executives will participate in multiple sessions and host an exhibition booth to engage with existing and prospective partners, underscoring the company’s drive to expand its commercial and strategic relationships in the global vaccine market.
During the conference, Vice President of Clinical Development Susanne Eder-Lingelbach is scheduled to present updates on Phase IV and real-world evidence studies for Valneva’s single-shot chikungunya vaccine IXCHIQ on April 1, 2026. The company highlighted that more than 12,000 people have already been vaccinated in a pilot campaign in Brazil with partner Instituto Butantan, while Chief Medical Officer Dr. Juan Carlos Jaramillo will join a high-level panel on chikungunya and mosquito-borne vaccines, reinforcing Valneva’s positioning as a key player in emerging arboviral vaccine markets.
The most recent analyst rating on (VALN) stock is a Hold with a $6.50 price target. To see the full list of analyst forecasts on Valneva stock, see the VALN Stock Forecast page.
Spark’s Take on VALN Stock
According to Spark, TipRanks’ AI Analyst, VALN is a Neutral.
The score is driven primarily by weak financial performance (large losses, negative free cash flow, and elevated leverage) and a bearish technical setup (below major moving averages with negative momentum). These are partially offset by a somewhat positive earnings-call outlook that maintained guidance, highlighted improved cash management and refinancing, and underscored pipeline catalysts, but near-term business and regulatory headwinds remain.
To see Spark’s full report on VALN stock, click here.
More about Valneva
Valneva SE is a specialty vaccine company that develops, manufactures and commercializes prophylactic vaccines targeting infectious diseases with unmet medical needs. The group applies multiple vaccine modalities to deliver first-, best- or only-in-class products, currently markets three proprietary travel vaccines, and is advancing a pipeline that includes the only Lyme disease vaccine candidate in advanced clinical development with Pfizer and a leading Shigella vaccine candidate.
Average Trading Volume: 46,273
Technical Sentiment Signal: Sell
Current Market Cap: $566.4M
For a thorough assessment of VALN stock, go to TipRanks’ Stock Analysis page.